Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels by Chauhan, Vikash P. et al.
ARTICLE
Received 5 Jul 2013 | Accepted 29 Aug 2013 | Published 1 Oct 2013
Angiotensin inhibition enhances drug delivery
and potentiates chemotherapy by decompressing
tumour blood vessels
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Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour
blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to
solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel
compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan
compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan
together are critical targets for decompressing tumour vessels. We demonstrate that the
angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, asso-
ciated with decreased expression of proﬁbrotic signals TGF-b1, CCN2 and ET-1, downstream
of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours
resulting in increased vascular perfusion. Through this physical mechanism, losartan
improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and
reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —
inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer
therapeutics.
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D
rug and oxygen delivery in tumours is dependent on
the organization and efﬁciency of perfused vessels1–3.
Solid stress (pressure from solid tissue components)
accumulates in tumours as cancer and stromal cells proliferate
in a conﬁned microenvironment created by crosslinked matrix
molecules4–6. The matrix stores and transmits this stress
throughout the tumour7, collapsing blood vessels to limit
perfusion8,9. Meanwhile, patients with low tumour perfusion—
presumably with extensive hypoxia and impaired drug delivery—
show poorer chemotherapy responses and shorter survival versus
patients with high perfusion10,11. Thus, there is an urgent need
for drugs that can target solid stress to improve blood perfusion
and drug delivery in tumours.
Stromal cells and matrix contribute to solid stress, but the
mechanisms through which these components interact to
compress tumour vessels remain unclear. Uncovering these
mechanisms could lead to novel paradigms for enhancing tumour
perfusion. In this study, we show that different tumour matrix
components produced by cancer-associated ﬁbroblasts (CAFs)
collaborate to compress vessels. We demonstrate that angiotensin
signalling blockade inactivates CAFs to reduce their production of
these matrix components while also reducing CAF density.
Through this mechanism, we ﬁnd that angiotensin receptor
blockers (ARBs) reduce solid stress, decompress tumour vessels,
increase drug and oxygen delivery and improve chemotherapy
outcomes. Thus, solid stress can be targeted by decreasing CAF
activity and agents that do so can improve tumour perfusion and
enhance chemotherapy.
Results
Hyaluronan and collagen collaborate to compress tumour
blood vessels. Hyaluronan has been proposed to be the primary
matrix molecule responsible for vessel compression12, but its exact
mechanism remains unclear. Hyaluronan interacts with collagen in
a complex manner13, and both contribute to the accumulation of
solid stress through these interactions5. Thus, we examined
whether collagen may also affect vessel compression (Fig. 1a,b).
We measured vessel perfusion (patency) in multiple orthotopic
tumours and compared it with hyaluronan and collagen levels.
Interestingly, we found that both hyaluronan and collagen area
fraction were inversely associated with perfused vessel fractions
(Fig. 1c). The mean of these matrix area fractions had an even
stronger inverse correlation with perfusion, indicating a complex
nonlinear relationship between the two matrix molecules and
perfusion. Surprisingly, we found that vessel perfusion did not
correlate with hyaluronan area fractions in tumours with low
collagen levels (Fig. 1d); rather, hyaluronan and perfusion were
inversely correlated only in collagen-rich tumours. In contrast,
perfusion inversely correlated with collagen area fraction in both
hyaluronan-rich and hyaluronan-poor tumours (Fig. 1e). These
ﬁndings indicate that collagen is needed for hyaluronan to exert
compression on blood vessels, suggesting that both are potential
targets for vessel decompression in desmoplastic tumours.
Angiotensin inhibition reduces stromal ﬁbrosis signalling. We
therefore sought a translatable therapy that targets both collagen
and hyaluronan. We recently found that the ARB losartan can
reduce collagen I production in CAFs by downstream inhibition
of transforming growth factor (TGF)-b1 activation14,15 through
thrombospondin-1 (TSP-1) inhibition16–18. As hyaluronan
synthesis is similarly TGF-b1 dependent, we expected that
losartan would also decrease hyaluronan production. We
generated transgenic FVB mice expressing the ﬂuorescent
protein dsRed driven by the promoter for a-smooth-muscle
actin (aSMA)19, a marker for activated CAFs. In these mice
(aSMAP-dsRed/FVB), we orthotopically implanted AK4.4
pancreatic tumour cells, treated these mice with losartan or
saline (control), and then isolated the CAFs (activated pancreatic
stellate cells) from their tumours using ﬂuorescence-activated cell
sorting (Supplementary Fig. S1). We conﬁrmed that CAF
expression of TGF-b1 and collagen I was reduced by losartan
(Fig. 2a,b). We then measured expression of hyaluronan syn-
thases 1–3 in these CAFs and found that hyaluronan synthases
1–3 were also greatly decreased by losartan (Fig. 2a,b). Thus,
losartan is a dual inhibitor of stromal collagen and hyaluronan
production.
Losartan rapidly reduces established tumour matrix levels14,
which implies that it degrades or destabilizes matrix through an
uncharacterized mechanism in addition to preventing matrix
production through TGF-b1. Connective tissue growth factor
(CCN2/CTGF), a matricellular protein, stabilizes the transient
ﬁbrosis produced by TGF-b1 activity20,21 and is downstream of
angiotensin signalling through TGF-b1 in other ﬁbrosis
diseases22,23, suggesting that losartan could be destabilizing the
matrix by inhibiting CCN2 expression. By comparing CAFs
isolated from losartan- versus saline-treated mice, we found that
losartan reduced expression of CCN2 (Fig. 2a,b). We next used
immunohistochemistry to assess how losartan affects CCN2,
active TGF-b1 and matrix levels in orthotopic E0771 and AK4.4
models, which recapitulate the desmoplasia observed in human
mammary adenocarcinoma and in human pancreatic ductal
adenocarcinoma, respectively (Supplementary Figs S2–S4). Losar-
tan reduced both CCN2 and active TGF-b1 in E0771 breast and
AK4.4 pancreatic tumours (Fig. 2c–f and Supplementary Fig. S5).
Further, losartan decreased collagen I and hyaluronan in both of
these tumours (Fig. 3a–d and Supplementary Figs S4, S6 and S7).
Thus, losartan decreases stromal matrix production through
TGF-b1 while potentially destabilizing the existing matrix
through CCN2. Collectively, these effects lead to a reduction in
collagen and hyaluronan levels in desmoplastic tumours.
Angiotensin inhibition decreases CAF density in tumours. As
the effects of losartan on matrix expression in tumours were
pronounced, and as angiotensin signalling has been previously
shown to activate ﬁbroblasts in other ﬁbrosis diseases24,25, we
next tested whether losartan could also reduce CAF density. We
found that losartan lowered the density of aSMAþ cells in E0771
and AK4.4 tumours (Fig. 3e,f and Supplementary Fig. S8), indi-
cating a decrease in activated CAFs. In other ﬁbrotic diseases,
ﬁbroblast activation occurs through endothelin-1 (ET-1) expres-
sion26 downstream of TGF-b127 and angiotensin signalling28.
Thus, we expected that losartan may reduce ET-1 expression by
CAFs. Indeed, in the CAFs isolated from losartan- or saline-
treated mice, we found that losartan decreased the expression of
ET-1 (Fig. 2a,b). Therefore, losartan seems to reduce activation of
ﬁbroblasts or stellate cells to aSMAþ CAF phenotype, leading to
a reduction in CAF density.
AT1 and AT2 signalling opposingly affect tumour ﬁbrosis. To
investigate how best to target angiotensin signalling, we next
investigated the role of angiotensin receptor signalling in tumour
desmoplasia. We ﬁrst studied the effects of the angiotensin-con-
verting enzyme inhibitor (ACE-I) lisinopril on the matrix,
because ACE-Is block both angiotensin-II-receptor-1 (AT1) and
angiotensin-II-receptor-2 (AT2) signalling. Intriguingly, lisinopril
reduced collagen I and hyaluronan in AK4.4 tumours to a lesser
extent than losartan, which blocks only AT1 signalling
(Supplementary Fig. S9). This suggests that AT2 inhibition leads
to increased matrix levels in tumours, in opposition to AT1
inhibition. We conﬁrmed this by implanting E0771 in knockout
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mouse models of AT1 (Agtr1a / ) and AT2 (Agtr2 / ). We
found that tumours in the AT1-knockout mice had lower levels of
collagen I and hyaluronan than tumours in wild-type mice
(Fig. 4a,b), whereas the tumours in AT2-knockout mice had
higher collagen I and hyaluronan levels than tumours in wild-
type mice (Fig. 4c,d), indicating that stromal AT2 signalling
inhibits tumour desmoplasia, whereas AT1 signalling promotes it.
Importantly, this result ﬁts with the known effects of angiotensin
signalling on ﬁbrosis in other diseases29–31. To conﬁrm the
relevance of stromal AT1 and AT2 inhibition, we measured the
expression of these receptors in CAFs and cancer cells from wild-
type mice. We found that CAFs isolated from AK4.4 tumours
express far more AT1 and AT2 than AK4.4 or E0771 cancer cells
(Fig. 4e). We conﬁrmed this result with immunohistochemistry in
E0771 tumours, where we found that a moderate fraction of CAFs
in these tumours express AT1 at high levels, whereas most other
cells express AT1 at low levels; most CAFs express high levels of
AT2, whereas a small fraction of other cells express similar AT2
levels (Fig. 4f,g). These results indicated that the cellular targets of
angiotensin blockers relating to matrix production are CAFs
rather than cancer cells. Thus, the antidesmoplasia beneﬁts of
ARBs are because of speciﬁc AT1 inhibition in tumour stroma,
and ACE-Is may not provide the same beneﬁts due to combined
AT1 and AT2 inhibition.
Angiotensin inhibition lowers solid stress in tumours. We next
investigated the effects of losartan on solid stress in tumours. We
measured solid stress in these tumours using our recently estab-
lished technique5. Losartan reduced solid stress in both E0771
and AK4.4 tumours (Fig. 5a), as well as in 4T1 breast and Pan-02
pancreatic tumours (Fig. 5b). We additionally tested a panel of
ARBs and found that they all reduced solid stress (Supplementary
Fig. S10), further suggesting that the mechanism of action is via
AT1 inhibition rather than an off-target effect of losartan. These
data indicate that angiotensin blockers may be capable of
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Figure 1 | Collagen and hyaluronan interact to compress tumour blood vessels. (a) Representative image from intravital multiphoton microscopy of
perfused tumour vessels (green) and collagen (blue), showing that high collagen levels colocalize with low perfusion in an E0771 breast tumour. Scale bar,
200mm. (b) Histology images of vascular perfusion in orthotopic AK4.4 pancreatic tumours with high versus low collagen levels. High local collagen I
levels (blue) appear to colocalize with collapsed vessels (red, collapsed; green/yellow, perfused) in vivo. Scale bar, 100 mm. (c) Correlation of
perfused vessel fraction versus tumour matrix area fractions in multiple orthotopic pancreatic tumour models (AK4.4 and L3.6pl) in mice. Following lectin
injection and animal killing, perfusion was quantiﬁed as the fraction of vessels that are both lectin- and CD31-positive out of all CD31-positive vessels.
Perfusion inversely correlates with both hyaluronan (R¼ 0.79, Po0.001, Pearson’s correlation) and collagen I (R¼ 0.78, Po0.001, Pearson’s
correlation), but has a stronger inverse correlation (R¼ 0.86, Po0.001, Pearson’s correlation) with the average matrix area fraction. (d) Grouping these
tumours into those with either low (o17%) or high (Z17%) collagen reveals that perfusion does not correlate (R¼ 0.33, Pearson’s correlation) with
hyaluronan in collagen-poor tumours but does inversely correlate (R¼ 0.71, P¼0.004, Pearson’s correlation) in collagen-rich tumours. (e) In contrast,
grouping the tumours into those with either low (o33%) or high (Z33%) hyaluronan shows that perfusion inversely correlates with collagen I in
both hyaluronan-poor (R¼ 0.73, P¼0.003, Pearson’s correlation) and hyaluronan-rich (R¼ 0.57, P¼0.040, Pearson’s correlation) tumours.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3516 ARTICLE
NATURE COMMUNICATIONS | 4:2516 | DOI: 10.1038/ncomms3516 | www.nature.com/naturecommunications 3
& 2013 Macmillan Publishers Limited. All rights reserved.
decompressing vessels in desmoplastic tumours by reducing solid
stress through their antimatrix effects.
Angiotensin inhibition decompresses tumour blood vessels.
We hypothesized that the reduction in solid stress by losartan
would increase vascular perfusion in our desmoplastic tumour
models. We found these tumours to be severely hypoperfused
(Supplementary Fig. S4): only 23% of vessels in E0771 breast
tumours and 21% in AK4.4 pancreatic tumours were perfused
with blood (Fig. 6a,b). Of note, collagen-rich areas seemed to
colocalize with low-perfusion areas (Fig. 3a). Losartan sig-
niﬁcantly improved the perfused vessel fraction to 43% in E0771
and 45% in AK4.4 (Fig. 6a,b). Losartan treatment also increased
the fraction of vessels with open lumen in E0771 and AK4.4
(Fig. 6c), further indicating vascular decompression as the
mechanism of action9. Interestingly, the open lumen fraction was
higher than the perfused vessel fraction in both models—perhaps
because of collapse or occlusion in feeding vessels or ﬂow ces-
sation and clot formation1. Importantly, losartan did not
signiﬁcantly improve perfusion in the well-perfused L3.6pl
tumour model, which has low collagen and 68% vessel
perfusion at baseline (Supplementary Fig. S11), conﬁrming the
ﬁndings of our previous study14. Thus, losartan can increase
blood perfusion in tumours by opening existing collapsed blood
vessels.
Despite the previous classiﬁcation of angiotensin inhibitors as
antiangiogenics32, we found that losartan did not reduce vascular
endothelial growth factor (VEGF) levels (Supplementary Fig.
S12), affect the CD31þ vessel density in these tumours
(Fig. 6d,e) or decrease vessel diameter (Supplementary Fig.
S13). Further, losartan increased the effective permeability of the
blood vessels for all sizes of nanoparticles (Supplementary Fig.
S14), which is inconsistent with the ‘vascular normalization’ effect
that results from antiangiogenic therapy33. Moreover, this dose
did not decrease blood pressure in a separate group of tumour-
bearing mice with advanced disease (Supplementary Fig. S15)14,
and correspondingly did not affect ﬂow rates in individual blood
vessels (Supplementary Fig. S16). As such, we conﬁrmed that
losartan does not improve perfusion by reducing vessel leakiness
or increasing blood ﬂow, as seen after vascular normalization11,33,
but rather does so through ‘microenvironmental normalization’.
Angiotensin inhibitors enhance drug and oxygen delivery. As
drug and oxygen delivery to tissues is governed by vascular
perfusion, we tested the effects of losartan on delivery to tumours.
We ﬁrst engaged a mathematical approach to analyse the efﬁ-
ciency of the vascular network for drug and oxygen delivery.
Using multiphoton microscopy, we imaged the perfused vessel
networks of E0771 tumours (Fig. 6a). On the basis of metrics of
intervascular spaces34, we found that losartan reduces the
distance drugs and oxygen must travel to reach tumour cells
(Fig. 6f and Supplementary Fig. S17). We then measured the total
tissue accumulation of the small-molecule chemotherapeutic
ﬂuorouracil (5-ﬂuorouracil; 5-FU). Losartan improved 5-FU
delivery to AK4.4 tumours while not affecting delivery to normal
organs (Fig. 6g). These data imply that this strategy for enhancing
delivery selectively affects tumours, which is expected, since
solid stress does not accumulate in most normal organs5. We then
studied oxygenation using phosphorescence quenching
microscopy35. We found that losartan treatment maintained
tumour oxygen levels in E0771 tumours, whereas control-treated
tumours showed a typical growth-dependent drop in oxygenation
(Fig. 6h,i). We conﬁrmed this decrease in tumour hypoxia by
using pimonidazole staining in E0771 and 4T1 (Fig. 6j and
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Figure 2 | Losartan decreases proﬁbrotic stromal activity in tumours. (a) Expression levels of ﬁbrosis-related genes in murine cancer-associated
ﬁbroblasts (CAFs) isolated from orthotopic AK4.4 pancreatic tumours. AK4.4 tumours were orthotopically implanted in aSMAP-dsRed/FVB mice, resulting
in aSMAþ CAFs that express dsRed. These mice were treated with losartan or saline (control), then the CAFs from their tumours were isolated
using ﬂuorescence-activated cell sorting for dsRed. The isolated control CAFs express high mRNA levels of collagen I (Col1), hyaluronan synthases
(HAS)1–2 (Has1, Has2), TGF-b1 (Tgfb1) and CCN2 (Ctgf), with low levels of HAS 3 (Has3) and moderate levels of ET-1 (Edn1). Levels normalized to GAPDH
expression. (b) Comparison of expression levels of ﬁbrosis-related genes in the CAFs isolated from losartan- or saline-treated (control) mice. Losartan
reduces the mRNA expression of each of these proﬁbrotic genes in CAFs (Po0.05, Student’s t-test). Levels normalized to saline control. (c) Histology
images showing the effect of losartan on tumour TGF-b1 expression. Scale bar, 100mm. (d) Immunohistochemical analysis of TGF-b1 expression with
losartan treatment. Losartan reduces the expression of TGF-b1 in E0771 (*P¼0.048, Student’s t-test) and AK4.4 tumours (**P¼0.044, Student’s t-test).
(e) Histology images showing the effect of losartan on tumour CCN2 expression. Scale bar, 100 mm. (f) Immunohistochemical analysis of CCN2 expression
with losartan treatment. Losartan reduces the expression of CCN2 in E0771 (*P¼0.044, Student’s t-test) and AK4.4 (**P¼0.046, Student’s t-test)
tumours. Scale bar, 100mm. Animal numbers n¼4 (CAF expression), n¼ 7–8 (E0771 TGF-b1, CCN2), n¼4–6 (AK4.4 TGF-b1, CCN2). Error bars indicate
s.e.m.
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Supplementary Figs S18 and S19). Thus, reducing solid stress
through ‘microenvironmental normalization’ with angiotensin
inhibitors increases the delivery of drugs and oxygen to tumours.
Angiotensin inhibition potentiates chemotherapy. Given these
effects on delivery, we tested losartan in combination with dox-
orubicin in E0771 and 4T1 tumours, or with 5-FU in AK4.4
tumours. We found that the combination of losartan with che-
motherapy signiﬁcantly delayed E0771, 4T1 and AK4.4 tumour
growth, whereas monotherapy had no effect (Fig. 7a–c and
Supplementary Fig. S20). Moreover, the combination of losartan
and chemotherapy increased median survival (time to death or
excessive tumour burden) for mice bearing E0771 and 4T1
tumours compared with monotherapy (Fig. 7d,e). Similarly, the
combination increased median survival (time to death) for mice
bearing AK4.4 tumours, whereas monotherapy did not extend
survival (Fig. 7f). Importantly, losartan alone—despite increasing
blood perfusion—did not shorten survival in any model. The
results of the combination for survival were somewhat better than
for primary tumour growth delay, indicating a possible effect on
metastases. Correspondingly, losartan slightly decreased metas-
tasis in E0771 (Supplementary Fig. S21), consistent with previous
studies36 and probably because of the role of angiotensin
signalling in promoting the metastatic cascade37,38. Of note, we
found that losartan combined with doxorubicin delayed tumour
growth in both immunodeﬁcient and immunocompetent models
of breast cancer (Fig. 7a,b and Supplementary Fig. S21), although
the effects appeared less pronounced in immunocompetent mice
even at high doses of doxorubicin. This might be attributed to
resistance induced by the immune microenvironment39.
Together, these data demonstrate that angiotensin inhibitors
can improve the effectiveness of small-molecule chemotherapeu-
tics through antimatrix effects.
Discussion
This study highlights the complex role of the tumour matrix as a
drug delivery barrier. Although the distribution of larger drugs
such as nanomedicines is hindered by steric interactions with
collagen, the matrix does not directly limit the distribution of
smaller, conventional chemotherapeutics40. Rather, the matrix
indirectly limits the delivery of conventional chemotherapy
through vascular compression. Both hyaluronan and collagen
ﬁbres contribute to solid stress in tumours: hyaluronan does so by
resisting compression, whereas collagen does so by resisting
tension and conﬁning the local microenvironment5. Our results
lead to a new model for how hyaluronan and collagen affect vessel
compression. As cancer and stromal cells proliferate, they attempt
to expand their local tumour microenvironment, exerting tensile
stress. This tensile stress stretches collagen ﬁbres in the micro-
environment, which store tensile elastic ‘strain’ energy and stiffen,
thereby resisting this expansion. The effect is to conﬁne these cells
such that the force they generate while proliferating becomes a
compressive stress. These cells cannot transmit compressive
stress perpendicularly to the ﬁbres of this stiffened collagen;
hence, this compressive stress is instead exerted largely on
hyaluronan in the local tumour microenvironment. Hyaluronan,
whose internal charges repel each other electrostatically and
trap water molecules, resists this compression, only storing
compressive ‘strain’ energy until maximally compressed. Beyond
this maximal compression, the excess compressive stress is
transmitted by hyaluronan to tumour vessels. These tumour
vessels, which lack the complete coverage by pericytes and
basement membrane that fortiﬁes mature vessels, are structurally
weak and cannot resist compression. If collagen levels are low in a
tumour, the microenvironment is more easily expanded by
proliferating cells and thus compressive stress is not produced to
as high a level. As a result, hyaluronan does not contribute to
vessel compression in collagen-poor tumours. If hyaluronan
levels are low, the compressive stress is not transmitted to vessels
to as great a degree. Thus, hyaluronan seems responsible for
transmitting compressive stress to vessels in all cases when there
is no direct cell contact, whereas collagen enables compressive
stress to be applied to hyaluronan by cells.
Analyses of retrospective clinical data suggest that the use of
AT1 blockers (ARBs) and ACE-Is to manage hypertension in
cancer patients receiving standard therapies is correlated with
longer survival in pancreatic and other cancers41–43, as well as a
reduced risk of recurrence in breast cancer44. However, a causal
relationship between the use of ARBs/ACE-Is and its clinical
beneﬁt—as well as the mechanism behind this potential effect—has
not been revealed. AT1 signalling has been shown to increase
VEGF expression by CAFs45, and both ACE-Is and ARBs can
decrease VEGF expression and angiogenesis46,47. It has therefore
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Figure 3 | Losartan reduces matrix and stromal density in tumours. (a)
Histology images showing the effect of losartan on tumour collagen levels
and perfusion. Scale bar, 100mm. (b) Immunohistochemical analysis of
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been assumed that their indirect antiangiogenic properties, through
downstream VEGF inhibition, beneﬁt survival additively. Our
current ﬁndings, in line with our previous report14, do not support
this antiangiogenic mechanism. Further, we detected no growth
delay or survival beneﬁt with losartan monotherapy in our study.
This is in contrast to the ability of angiotensin signalling through
AT1 to promote tumour growth and metastasis32,37,38,48,49, with
signalling through AT2 hindering growth50. This is perhaps
because these growth inhibitory effects are primarily seen at much
higher doses of ARBs36,46,51 or with long-term treatment52; indeed,
when used at low doses, ARBs have been shown by others to not
cause a growth delay47. It is also possible that this VEGF inhibition
is because of direct effects of angiotensin inhibitors on cancer cells,
and that our models do not respond similarly because the cancer
cells used do not express high levels of AT1 or AT2. These
inconsistent data notwithstanding, it should be noted that
antiangiogenic therapy with bevacizumab has failed to prolong
survival in desmoplastic tumours such as breast and pancreatic
cancer3, casting doubt on a possible antiangiogenic mechanism for
the beneﬁts observed with angiotensin inhibitors.
Here we have found that angiotensin inhibitors actually
increase vessel perfusion through vascular decompression, doing
so by reducing stromal activity and production of matrix
components responsible for compression. Notably, these drugs
are the ﬁrst to target all stromal components (CAFs, hyaluronan
and collagen) known to contribute to solid stress5. Our ﬁndings
also suggest that AT2 agonists or inhibitors of downstream
signalling through TGF-b1, CCN2 or ET-1 may similarly reduce
solid stress to enhance chemotherapy, although such agents have
not been tested in this way. Similarly, angiotensin (1–7), a MAS
agonist that can reduce CAF matrix production, may be useful for
targeting solid stress53. Meanwhile, there are challenges to
address for translation. Deleterious effects on blood pressure
may contraindicate angiotensin inhibitors for some patients14,54.
Further, we expect that angiotensin inhibitor distribution into
tumours may be the most important factor controlling efﬁcacy:
drugs displaying a lack of tissue penetration (such as candesartan)
would therefore be poor candidates relative to those with high
penetration (such as losartan and telmisartan)55. Indeed, the
inadequate tumour penetration of candesartan may explain why
it only improved chemotherapy outcomes modestly, when
comparing high versus low candesartan doses, in a recent
pancreatic cancer study54. These factors are why losartan was
selected over other angiotensin inhibitors for a recently initiated
clinical trial in pancreatic cancer (NCT01821729) at
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Figure 4 | Stromal angiotensin signalling induces matrix production in tumours. (a) Tumour collagen and (b) hyaluronan levels in angiotensin-II-
receptor-1 (AT1)-knockout mice. Orthotopic E0771 breast tumours implanted in AT1-knockout mice (Agtr1a / ) have (a) a lower collagen I area fraction
(*P¼0.026, Student’s t-test) and (b) a lower hyaluronan area fraction (*P¼0.011, Student’s t-test) than E0771 tumours implanted in wild-type C57BL/6
mice. (c) Tumour collagen and (d) hyaluronan levels in angiotensin-II-receptor-2 (AT2) knockout mice. Orthotopic E0771 breast tumours implanted in AT2-
knockout mice (Agtr2 / ) have (c) a higher collagen I area fraction (*P¼0.047, Student’s t-test) and (d) a higher hyaluronan area fraction (*P¼0.012,
Student’s t-test) than E0771 tumours implanted in wild-type C57BL/6 mice. Tumours were time- and size-matched atB200mm3. (e) Expression of AT1
(Agtr1a and Agtr1b genes) and AT2 (Agtr2 gene) mRNA in murine cancer-associated ﬁbroblasts (CAFs) and cancer cells. CAFs isolated from AK4.4
tumours express over one order of magnitude more AT1 than either E0771 or AK4.4 cancer cells. Similarly, the CAFs express over two orders of magnitude
more AT2 than either E0771 or AK4.4 cells. (f) Expression of AT1 (red) in aSMAþ CAFs (green) and cancer cells in tumours. We imaged CAFs based on
aSMAþ expression in E0771 tumours. We found that some CAFs in these tumours express AT1 at high levels, whereas other cells express AT1 at low
levels. Colocalization is shown in yellow. Scale bar, 25mm. (g) Expression of AT2 (red) in aSMAþ CAFs (green) and cancer cells in tumours. Most CAFs
express high levels of AT2, whereas some other cells express similar AT2 levels. Colocalization is shown in yellow. Scale bar, 25mm. Animal numbers
n¼4–5. Error bars indicate s.e.m.
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Figure 5 | Losartan targets solid stress in tumours. (a) Solid stress levels
in tumours after angiotensin inhibition using losartan. Solid stress was
assessed using an ex vivo technique involving the measurement of the
extent of tumour tissue relaxation (tumour opening relative to tumour
diameter) following a stress-releasing incision, with larger openings
indicating higher stress5. Through its antimatrix effects, losartan reduces
solid stress in E0771 (*P¼0.049, Student’s t-test) and AK4.4
(**P¼0.043, Student’s t-test). (b) Losartan reduces solid stress in
additional models, including 4T1 breast tumours (*P¼0.036, Student’s t-
test) and Pan-02 pancreatic tumours (**P¼0.0092, Student’s t-test).
Animal numbers n¼ 5 (E0771), n¼8–9 (AK4.4), n¼ 10–11 (4T1), n¼4–8
(Pan-02). Error bars indicate s.e.m.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms3516
6 NATURE COMMUNICATIONS | 4:2516 | DOI: 10.1038/ncomms3516 | www.nature.com/naturecommunications
& 2013 Macmillan Publishers Limited. All rights reserved.
Massachusetts General Hospital. Regardless, the safety and low
cost of ARBs and ACE-Is—along with their potentiation of
conventional chemotherapy—make a strong case for repurposing
angiotensin inhibitors as adjuncts for cancer therapies.
Methods
Drug preparation. Angiotensin inhibitors (losartan, lisinopril, valsartan and
candesartan) were obtained as pills, crushed and dissolved in PBS (for losartan and
lisinopril) or PBS with 5% ethanol (for valsartan and candesartan) over 24 h. The
solutions were then sterile ﬁltered for injection. Doxorubicin and 5-FU were
obtained as solutions for injection. All drugs were purchased from the pharmacy at
Massachusetts General Hospital.
Tumour models. AK4.4 cells (KrasG12D and p53þ / ) were kindly provided by
Dr Nabeel Bardeesy, and were isolated from mice generating spontaneous
pancreatic tumours56 (Ptf1-Cre/LSL-KrasG12D/p53Lox/þ ). Orthotopic pancreatic
tumours were generated by implanting a small piece (1mm3) of viable tumour
tissue (from a source tumour in a separate animal) into the pancreas of a 6–8-
week-old male FVB (AK4.4 model) or C57BL/6 (Pan-02 model) mouse. Orthotopic
breast tumours were similarly generated by implanting a chunk of viable tumour
tissue into the mammary fat pad of a 6–8-week-old female severe combined
immunodeﬁcient (SCID) mouse (E0771 and 4T1 models) or C57BL/6 mouse
(E0771 syngeneic model). For AT1- and AT2-knockout studies, E0771 cells were
implanted by injection into the mammary fat pad of 6–8-week-old female C57BL/
6, agtr1a / (ref. 57) or agtr2 / (ref. 58) mice. All animal procedures were
carried out following the Public Health Service Policy on Humane Care of
Laboratory Animals and approved by the Institutional Animal Care and Use
Committee of Massachusetts General Hospital.
Vessel perfusion and hypoxia histology. For breast tumours, mice bearing
orthotopic E0771 were split into time- and size-matched (B100mm3) treatment
groups. For pancreatic tumours, mice bearing orthotopic AK4.4 were split into
treatment groups 6 days post implantation. The mice were then treated with
40mg kg 1 losartan or an equal volume of PBS intraperitoneally each day for
6 (E0771) or 7 (AK4.4) days. On the day of the last treatment, mice were slowly
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Figure 6 | Losartan decompresses tumour vessels to increase drug and oxygen delivery. (a) Representative images from intravital multiphoton
microscopy of perfused tumour vessels (green) and collagen (blue), showing that losartan increases the density of perfused vessels in an E0771 breast
tumour. Scale bar, 1mm. (b) Perfused vessel fractions after angiotensin inhibition using losartan. Losartan increases the fraction of vessels that are perfused
in orthotopic E0771 breast (*P¼0.038, Student’s t-test) and AK4.4 pancreatic (**P¼0.039, Student’s t-test) tumours. (c) Losartan also increases the
fraction of vessels with open lumen in E0771 (*P¼0.040, Student’s t-test) and AK4.4 (**P¼0.015, Student’s t-test) tumours, indicating decompression as
the mechanism9. (d) Vessel density and (e) vessel length following angiotensin inhibition using losartan. Losartan does not affect vessel density, as
quantiﬁed by the vessel number density (d) and the total vessel length (e), indicating no antiangiogenic effect at this 40mg kg 1 dose. (f) Representative
images from intravital optical frequency-domain imaging of perfused vessels with losartan treatment. E0771 tumours in control mice have a low density and
poor distribution of perfused vessels in three dimensions, whereas losartan-treated mice showed a more even distribution and higher density of perfused
vessels. Scale bar, 1mm. (g) Small-molecule drug delivery to tumours and various organs after angiotensin inhibition with losartan. Losartan increases the
accumulation of the small-molecule chemotherapeutic 5-FU in AK4.4 pancreatic tumours by 74% (*P¼0.0063, Student’s t-test), while not affecting
accumulation in the normal organs. (h) Oxygen delivery to tumours measured by phosphorescence quenching microscopy during angiotensin inhibition
using losartan, with (i) representative images. Losartan maintains the level of oxygenation (h) in the tissue, versus control tumours that become
progressively more hypoxic with time (*P¼0.030, Student’s t-test) as the tumours grow from 3 to 5mm in diameter. Losartan increases oxygenation in
some tumours (i) whereas all control tumours decrease in oxygen levels. Losartan also appears to result in a more homogenous distribution of well-
oxygenated tumour tissue. Scale bar, 100mm. (j) Hypoxic fraction in tumours measured by pimonidazole injection and staining following angiotensin
inhibition with losartan. Losartan decreases the hypoxic fraction in E0771 tumours (*P¼0.019, Student’s t-test) because of the increase in oxygen delivery.
Animal numbers n¼ 7–9 (vessels), n¼4–5 (vessel lumen), n¼4 (drug delivery), n¼6 (oxygen delivery), n¼ 6–7 (hypoxia). Error bars indicate s.e.m.
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(B2min) injected with 100 ml of 1mgml 1 biotinylated lectin (Vector Labs),
administered via the retro-orbital sinus 5min before tumour removal. For hypoxia
studies, the mice were also injected with 60mg kg 1 of pimonidazole at
10mgml 1 1 h before tumour removal. The tumours were then excised, ﬁxed in
4% formaldehyde in PBS (30minmm 1 diameter of tissue), incubated in 30%
sucrose in PBS overnight at 4 C and frozen in optimal cutting temperature
compound (Tissue-Tek). Transverse tumour sections, 40 mm thick, were immuno-
stained with antibodies to endothelial marker CD31 (MEC13.3 antibody, Bio-
sciences (BD), 1:100 dilution) and counterstained with 40 ,6-diamidino-2-pheny-
lindole (Vector Labs). Collagen I and hyaluronan were, respectively, detected using
the LF-68 antibody (1:50 dilution) provided by Dr Larry Fisher (NIDCR) and a
biotinylated hyaluronan proteoglycan fragment (385911, Calbiochem), as pre-
viously described40. Staining for aSMA (C6198 antibody, Sigma, 1:100 dilution),
active TGF-b1 (G122A antibody, Promega, 1:15 dilution), CCN2 (TP-243
antibody, Torrey Pines, 1:100 dilution), AT1 (ab18801 antibody, Abcam, 1:100
dilution) and AT2 (AAR-012 antibody, Alomone, 1:200 dilution) were carried out
in 10mm sections. For the detection of collagen I in AK4.4, KPC and human
pancreatic ductal adenocarcinoma, the parafﬁn-embedded sections were treated
with a pH-9.0 antigen retrieval solution and counterstained with haematoxylin.
Histological image analysis. Eight random ﬁelds (four interior and four per-
iphery) at  20 magniﬁcation were taken from each slide using a confocal
microscope (Olympus). For vascular analysis, vessels were skeletonized and seg-
mented using a custom, semi-automated tracing program developed in MATLAB
(The MathWorks), allowing the removal of structures under 30 pixels and regions
of autoﬂuorescence. For perfusion fraction, the number of vessels counted by this
program with colocalization of lectin and CD31 staining was divided by the
number of vessels counted with CD31 staining. For vessel metrics, including dia-
meter and density, the program determined the average size of all counted vessels
and their length, as well as the count per area. For open versus closed lumen
quantiﬁcation, vessels were analysed by eye and a vessel was counted as open if it
had a clearly visible lumen throughout its length. Images of collagen I, hyaluronan,
pimonidazole (hypoxia) aSMA, active-TGF-b1 and CCN2-stained sections were
analysed based on the area fraction of positive staining. Identical analysis settings
and thresholds were used for all tumours.
CAF studies. We generated aSMAP-dsRed/Tie2P-GFP/FVB double-transgenic
mice by crossing Tie2P-GFP/FVB mice59 with aSMAP-dsRed mice19. Once
established, this line was backcrossed to FVB mice for at least 10 generations.
CAFs were isolated from AK4.4 tumours implanted in 6–8-week-old male mice of
this line. The mice were treated with 40mg kg 1 losartan or PBS for 7 days, and
then the tumours were collected and aSMAþ cells were isolated based on dsRed
ﬂuorescence using ﬂuorescence-activated cell sorting (BD Biosciences). These cells
were analysed with quantitative reverse transcriptase-PCR for messenger RNA of
Col1a1 (F 50-GCTCCTCTTAGGGGCCACT-30 , R 50-CCACGTCTCACCATTGG
GG-30), Has1 (F, 50-GGCGAGCACTCACGATCATC-30, R 50-AGGAGTCCATA
GCGATCTGAAG-30), Has2 (F 50-TGTGAGAGGTTTCTATGTGTCCT-30 , R 50-
ACC GTA CAG TCC AAA TGA GAA GT-30), Has3 (F 50-CCTGGAGCACCGT
CGAATG-30 , R 50-CCTTGAGGTTTGGAAAGGCAA-30), Tgfb1 (F 50-GCAGTG
GCTGAACCAAGGA-30 , R 50-AGCAGTGAGCGCTGAATCG-30), Ctgf (F 50-CAA
AGCAGCTGCAAATACCA-30, R 50-GTCTGGGCCAAATGTGTCTT-30) and
Edn1 (F 50-GCACCGGAGCTGAGAATGG-30 , R 50-GTGGCAGAAGTAGACAC
ACTC-30). We also analysed these cells, as well as AK4.4 and E0771 cells, for
Agtr1a (F 50-AACAGCTTGGTGGTGATCGTC-30, R 50-CATAGCGGTATAGAC
AGCCCA-30), Agtr1b (F 50-TGGCTTGGCTAGTTTGCCG-30 , R 50-ACCCAGTCC
AATGGGGAGT-30) and Agtr2 (F 50-AACTGGCACCAATGAGTCCG-30 ,
R 50-CCAAAAGGAGTAAGTCAGCCAAG-30). Expression levels were normalized
to the control (GAPDH) and losartan-treated levels were normalized to the
PBS controls.
Solid stress. Solid stress was measured using the tumour opening technique5.
When the tumours reached a size of B1 cm in diameter, the mice were
anaesthetized. Subsequently, each tumour was excised, washed with Hank’s
balanced salt solution and its three dimensions were measured. Each tumour was
0
2
4
6
8
Ti
m
e 
to
 d
ou
bl
e
vo
lu
m
e 
(da
ys
)
0.0
0.2
0.4
0.6
0.8
1.0
0 6 12 18 24 30
Su
rv
ivi
ng
 fr
ac
tio
n
*
E0771
* **
Saline + saline
Losartan + saline
Saline + chemotherapy
Losartan + chemotherapy
0 6 12 18
*
0
2
4
6
8
Ti
m
e 
to
 d
ou
bl
e
vo
lu
m
e 
(da
ys
)
0.0
0.2
0.4
0.6
0.8
1.0
Time (days)Time (days)
Su
rv
ivi
ng
 fr
ac
tio
n
4T1
* **
AK4.4
0
200
400
Tu
m
ou
r s
iz
e
(m
m3
)
*
0 6 12 18 24
0.0
0.2
0.4
0.6
0.8
1.0
Time (days)
Su
rv
ivi
ng
 fr
ac
tio
n
*
Figure 7 | Losartan potentiates chemotherapy. (a) Quantiﬁcation of tumour growth rates, based on the time to reach double the initial volume, for
orthotopic E0771 breast tumours in response to treatment with losartan or saline control (40mg kg 1 daily from day 0 onwards) in combination with
either the small-molecule chemotherapeutic doxorubicin or saline control (2mg kg 1 every 3 days from day 1 onwards). Doxorubicin and losartan
monotherapy induce no signiﬁcant growth delay versus the control treatment in these aggressive tumours. In contrast, their combination greatly limits
tumour growth (*P¼0.040, Student’s t-test). (b) Quantiﬁcation of tumour growth rates, based on the time to reach double the initial volume, for
orthotopic 4T1 breast tumours using the same treatments as with E0771. Doxorubicin and losartan monotherapy induce no signiﬁcant growth delay versus
the control treatment. In contrast, their combination greatly limits tumour growth (*P¼0.024, Student’s t-test). (c) Volumes of orthotopic AK4.4
pancreatic tumours on day 7 in response to treatment with losartan or saline control (40mg kg 1 daily from day 0 to 7) in combination with either the
small-molecule chemotherapeutic 5-FU or saline control (60mg kg 1 on days 2 and 6). 5-FU and losartan monotherapy induce no signiﬁcant growth delay
versus the control treatment, whereas their combination greatly inhibited tumour growth (*P¼0.0085, Student’s t-test). (d) Animal survival for E0771-
bearing mice following the initiation of treatment. Doxorubicin monotherapy improves survival versus the control (*P¼0.048, log-rank test), whereas the
combination of doxorubicin and losartan enhances this survival increase versus doxorubicin monotherapy (**P¼0.014, log-rank test). (e) Animal survival
for 4T1-bearing mice following the initiation of treatment. Doxorubicin monotherapy improves survival versus the control (*P¼0.045, log-rank test),
whereas the combination of doxorubicin and losartan enhances this survival increase versus doxorubicin monotherapy (**P¼0.050, log-rank test).
(f) Animal survival for AK4.4-bearing mice following the initiation of treatment. The combination of 5-FU and losartan enhances survival versus 5-FU
(*P¼0.019, log-rank test) or losartan monotherapy (*P¼0.027, log-rank test). Animal numbers n¼ 5–6 (E0771, AK4.4 growth), n¼ 3–8 (AK4.4 survival),
n¼ 6–7 (4T1). Error bars indicate s.e.m. Statistical tests were corrected for multiple comparisons using the Holm–Bonferroni method.
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cut along its longest axis, to a depth of 80% of its shortest dimension, using a
scalpel. The tumours were allowed to relax for 10min in Hank’s balanced salt
solution to diminish any transient, poro-elastic responses. Afterwards, the opening
resulting from the cut was measured at the middle of the cut at the surface of the
tumour. Solid stress is proportional to the size of the opening relative to the size of
the dimension perpendicular to the cut.
Drug delivery. Mice bearing orthotopic AK4.4 were split into treatment groups 6
days after implantation. The mice were then treated with 40mg kg 1 losartan or
an equal volume of PBS intraperitoneally each day for 7 days. On the day of the last
treatment, mice were injected with 100mg kg 1 5-FU, administered retro-orbitally
30min before tumour and organ removal. The tissue was dabbed of excess blood
and then snap-frozen in liquid nitrogen for analysis. 5-FU was isolated from the
tissues and measured using liquid–liquid extraction followed by reverse-phase
HPLC with tandem mass-spectrometry.
In vivo imaging. For imaging studies, E0771 tumours were implanted in mice
bearing mammary fat pad chambers33 and allowed to grow toB3mm in diameter.
Multiphoton imaging was carried out on a custom-built multiphoton laser-
scanning microscope using a confocal laser-scanning microscope body (Olympus
300, Optical Analysis) and a broadband femtosecond laser source (High
Performance MaiTai, Spectra-Physics)60. Images were taken atB60mW at sample
surface. Mosaic images were taken in raster pattern using a motorized stage (H101,
Prior Scientiﬁc, Inc.) and customized automation software (LabView, National
Instruments). Imaging studies were performed with a  20 magniﬁcation, 0.95NA
water immersion objective (Olympus XLUMPlanFl, 1-UB965, Optical Analysis).
Optical frequency-domain imaging was carried out after 7 days of treatments using
a custom-built microscope61.
Tissue oxygenation. We measured pO2 in the tumours using phosphorescence
quenching microscopy35, which was adapted to multiphoton microscopy. An
oxygen-sensitive porphyrin, Oxyphor R2 (Oxygen Enterprises) was injected retro-
orbitally 12 h before imaging, and was reinjected immediately before imaging along
with 2MDa ﬂuorescein isothiocyanate-dextran (Sigma-Aldrich) for functional
vascular tracing. A mosaic image of the tumour was collected, and oxygen was then
measured in an evenly spaced 12 12 grid at four depths (60, 120, 180 and
240mm) in the tumour. At each point in the grid, the phosphorescence lifetime of
the probe was measured after each of several repeated brief intense pulses of
1,020 nm laser light, and these lifetime measurements were combined. A two-
component model was used to calculate the oxygen tension from each lifetime
measurement, accounting for binding and quenching of the probe by both oxygen
and proteins. The grid was then overlaid on the mosaic to make an oxygen map.
Effective permeability. Effective permeability (transvascular ﬂux) studies were
carried out using a mixture of nanoparticles with diameters of 12 nm (476 nm
emission), 60 nm (540 nm emission) and 125 nm (625 nm emission)33.
Concentrations were adjusted with in vitro calibration to result in roughly equal
photoluminescence intensity for all three nanoparticle samples under 800 nm
multiphoton excitation. Following retro-orbital injection of 200 ml with these
concentrations, multiphoton imaging was carried out as described above at depths
from 0 to 201mm, with 2.76 mm steps and 2.76 2.76 mm pixels. Images were taken
every 3min at each region of interest for a duration of 1 h. Images were analysed
using custom analysis software developed in Matlab (The MathWorks)33,62. The
analysis approach involved three-dimensional (3D) vessel tracing to create vessel
metrics and a 3D map of voxel intensity versus distance to the nearest vessel over
time. Images were also corrected for sample movement over time with 3D image
registration. The effective permeability (normalized transvascular ﬂux) was
calculated using JtSv Cv Cð Þ ¼ Pef f ¼ limt!0 @@t
R1
r¼R CðrÞr@r
Cv Cð ÞR , where Jt is the transvascular
ﬂux, Sv is the vessel surface area, Cv is the concentration of the probe in the vessel,
C is the concentration of the probe immediately extravascular, Peff is the effective
permeability, t is the time after the initial image, r is the distance from the vessel
central axis and R is the vessel radius at that point along the vessel. Fluorescence
intensities were used as these concentrations. The calculation was made as an
average over the entire imaged volume for each tumour.
Individual tumour vessel blood ﬂow. Red blood cell (RBC) velocity was mea-
sured using intravital microscopy with the residence time line scanning technique
in mice bearing orthotopic E0771 or 4T1 mammary tumours63. RBCs from a donor
mouse were labelled ex vivo with 1,10-dioctadecyl-3,3,30 ,30-
tetramethylindodicarbocyanine perchlorate. These labelled RBCs were
administered to mice bearing orthotopic E0771 or 4T1 mammary tumours via
retro-orbital injection at a ratio of 3–5 labelled RBCs per 100 RBCs. Multiphoton
imaging was carried out, applying laser scanning along a single line that intersects
each vessel of interest. Repeated scanning along this line generated ﬂuorescence
intensity data along the line over time (x–t), in which ‘images’ of the ﬂuorescent
RBCs are compressed or elongated depending on the residence time of the cells in
the scan. Velocities were extracted using vrbc ¼ Lrbc fnscans sinðaÞ, where vrbc is the RBC
velocity, Lrbc is the RBC length (7 mm), f is the line scan frequency (scans s 1),
nscans is the number of consecutive scan lines that detected the RBC and a is the
angle between vessel and line scan.
Breast tumour growth and survival studies. Mice bearing orthotopic E0771 or
4T1 breast tumours were split into treatment groups, time-matched for time after
implantation and size-matched for tumour volume at this time (105mm3 in E0771
and 141mm3 in 4T1). The mice were then treated with 40mg kg 1 losartan or an
equal volume of PBS intraperitoneally on day 0 and each subsequent day. The mice
were then treated with either 2mg kg 1 (SCID) or 5mg kg 1 (C57BL/6) doxor-
ubicin, or an equal volume of saline, by intraperitonteal injection every 3 days
beginning on day 1 (after two losartan or PBS treatments). Doxorubicin or control
treatments were carried out 4 h after losartan or control treatments. The primary
tumours were then measured every 1–2 days, beginning on day 0, using calipers.
Tumour growth was quantiﬁed using the time for each to reach double (SCID) or
triple (C57BL/6) its initial volume. Animal survival was quantiﬁed based on the
time of death after initiation of treatment or time to reach excessive tumour burden
(1000mm3). For metastasis studies, mouse lungs were collected at the killing and
were ﬁxed in Bouin’s solution. Macrometastases were counted using a
stereomicroscope.
Pancreatic tumour growth and survival studies. Mice bearing orthotopic AK4.4
pancreatic tumours were split into treatment groups, size-matched for tumour
volume (22mm3) by surgical exposure, 6 days after implantation. The mice were
treated with 40mg kg 1 losartan or an equal volume of PBS intraperitoneally on
day 7 after implantation and each subsequent day. The mice were then treated with
either 60mg kg 1 5-FU or an equal volume of saline by intravenous injection
on days 9 and 13 after implantation. Tumours were extracted on day 14 for
measurement using calipers. Tumour growth was quantiﬁed using the size at day 14.
For survival studies, mice were treated daily with losartan or PBS starting on day 3
after implantation until day 13, and then with 5-FU or saline on days 5, 9 and 13.
Mean arterial pressure. Mice bearing orthotopic AK4.4 pancreatic tumours were
used for blood pressure measurements. Mean arterial pressure was measured by
cannulation of the left carotid artery after a longitudinal skin incision above the
trachea14. After removal of the submandibular gland, the paratracheal muscles
were split and the left carotid artery was isolated. The cranial end of the artery was
ligated with a 6–0 silk suture and another suture was tied loosely around the central
part of the artery. A metal clamp was then positioned caudally to stop blood ﬂow
during the cannulation. A polyethylene catheter (PE-10, Becton-Dickinson) ﬁlled
with heparinized saline was then inserted through a hole cut proximally to the
cranial ligature, and the other suture was tied tightly around the tubing and artery.
The clamp was then removed and the end of the tubing was connected to a
pressure transducer for the measurement of blood pressure.
Mathematical analysis and modelling. The analysis was carried out on mosaic
images of whole tumours taken with multiphoton microscopy after injection of
2MDa ﬂuorescein isothiocyanate-dextran as a perfused vessel tracer. Details of the
models and corresponding equations are described in Baish et al34.
Statistical analysis. The data are presented as means with s.e. Groups were
compared using a Student’s t-test, paired or unpaired, except for animal survival
studies where a log-rank test was used. In pairwise comparisons within studies
where multiple comparisons were made, P-values were adjusted using Holm’s
method.
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